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Abstract
Cardiac metastasis of malignant phyllodes tumor is very rare. We herein report a rare case that developed cardiac
metastasis from malignant phyllodes tumor. A 38-year-old woman underwent lumpectomy, and the final pathological
findings showed the 5-cm malignant phyllodes tumor partially containing 1 cm of squamous cell carcinoma.
Four months after the first surgery, a local recurrence of malignant phyllodes tumor and distant metastases to
the bone, lung, pulmonary main trunk, and right ventricle were detected. Mass reduction surgery of cardiac
metastasis of the malignant phyllodes tumor was performed to avoid sudden death. In immunohistochemical
findings, the tumor was suspected to be originated in myoepithelial cells because of the expression of smooth
muscle lineage including α-smooth muscle actin and Calponin1 and highly malignant characteristics showing
MIB-1 and p53 highly positive with angiogenesis. Further studies are needed to clarify the effective treatment
to these tumors.
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Background
Phyllodes tumor is a fibroepithelial neoplasm of the fe-
male breast which was classified as benign, borderline
malignant, or malignant state, accounting for 0.5 % of
all breast tumors [1]. Approximately 50 % of this tumor
is benign, and 25 % is borderline [2]. However, it can
recur locally in any state [3]. On the other hand, 16 to
30 % of phyllodes tumors were reported to be histologi-
cally malignant [4]. Surgical excision is the only effective
treatment. Cardiac metastasis of phyllodes tumor is very
rare and hard to manage. We herein report a rare case of
a patient with a malignant phyllodes tumor that metasta-
sized to the right ventricle and received cardiac surgery.
Case presentation
A 38-year-old woman visited our hospital with a firm
mass in her left breast. The mass had increased in size in
a few months. Ultrasounds showed an over 5-cm hypoe-
choic mass on lower inner quadrant of her left breast. It
was diagnosed borderline phyllodes tumor by ultrasound-
guided needle biopsy.
The patient underwent lumpectomy. Final pathological
findings showed the malignant phyllodes tumor mea-
sured 5.0 × 4.7 × .4.0 cm, partially containing 1.0 × 0.9 cm
of squamous cell carcinoma (SCC), pT1b N0 M0 stage I,
stating that nuclear grade was 2, estrogen receptor was
6, and progesterone receptor was 0 by Allred score, and
human epidermal growth factor receptor type2 (HER2)
status was negative (Figs. 1 and 2). SCC was not in-
cluded in the phyllodes tumor but partially contacted
with the tumor by epithelial cells.
Because of the margin-positive of phyllodes tumor
and the hormone receptor-positive presence of SCC, an
additional mastectomy and sentinel node biopsy were
performed 1 month after the first surgery. Residual ma-
lignant phyllodes tumor was detected but SCC was not
found on the surgical specimen. The patient started to
receive tamoxifen for the hormone receptor-positive
SCC in adjuvant setting.
Four months after the first surgery, she presented in
our hospital a 1-month history of a breast tumor on her
left chest wall, 1-week history of edema on her face and
bilateral legs, dyspnea at rest, back pain, and declining of
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urine volume, all of which had progressively worsened in
a few days. Her consciousness was clear and vital signs
were normal, and The Eastern Cooperative Oncology
Group performance status was 1. Physical examination re-
vealed edema on bilateral feet and face that indicated con-
gestive heart failure. Chest X-rays showed multiple lung
metastasis, enlargement of cardiothoracic ratio (54 %),
and protrusion of the left second arch showing pulmonary
artery. Computed tomography scan revealed a local recur-
rence on the left breast, embolism to the right ventricle
and pulmonary main trunk, bone destruction (fourth thor-
acic vertebrae, Th4), and lung metastasis. Transthoracic
echocardiography showed a 5.8 × 4.1 × 7.0-cm mass with
homogeneous echogenicity that occupied nearly the entire
right ventricular (RV) cavity and almost obstructed RV
outflow tract (RVOT). It also involved the pulmonary
valve and extended to the pulmonary artery. The mass
had invaded the RV septum to the endocardium and then
grew forward to the RV reaching the pulmonary artery.
There were a few evidences of pericardial effusions. We
diagnosed a chest wall recurrence of malignant phyllodes
tumor and distant metastases to the bone, lung, pulmon-
ary main trunk, and right ventricle.
After multidisciplinary discussion among breast sur-
geon, medical oncologist, radiologist, cardiologist, and
cardiac surgeon, the patient decided to undergo urgent
mass reduction surgery releasing the severe stenosis of
RVOT to avoid sudden death. The histological finding
revealed a metastasis of malignant phyllodes tumor to
right ventricle.
She was discharged from the hospital on the 12th post-
operative day. However, on the 66th day after the cardiac
surgery, she died from heart failure because of re-
enlargement of the residual tumor in the right ventricle.
Fig. 1 The primary phyllodes tumor in the left breast had leaf-like architecture of epithelial cells and high-grade malignant stromal overgrowth
(H&E, ×4 (a), magnificent). The tumor partially containing 1.0 × 0.9 cm SCC in the primary site: SCC partially have contact with epithelial cells of
phyllodes tumor (H&E, ×4 (b), magnificent). AE1/3 was positive on SCC and negative on the phyllodes tumor (×10 (c), magnificent). H&E, hematoxylin
and eosin; SCC, squamous cell carcinoma
Fig. 2 Autopsy specimen of the heart in macroscopic findings (a): Cardiac tumor was 10 × 7 × 7 cm, occupied 70 % of the right ventricle. Right
ventricle (RV) was almost in stenosis. Spindle tumor cells with highly stromal overgrown involving the heart were similar to primary malignant
tumor cells in the metastatic site (H&E, ×10 (b), magnificent)
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Pathological findings
Autopsy showed the presence of local recurrence and
multiple distant metastases to the lung, bone (Th4),
diaphragm, and cardiac ventricle of malignant phyl-
lodes tumor (Fig. 3a). Spindle tumor cells involving the
heart were similar to primary malignant tumor cells in
microscopic findings (Fig. 3b). SCC was not involved in
any metastatic sites. In immunohistochemical findings
of primary tumor, pan-cytokeratin AE1/AE3 was negative
on the phyllodes tumor site while positive on SCC site
(Fig. 1d, e). The specimen of metastatic tumor to the right
ventricle showed that pan-cytokeratin AE1/AE3 was nega-
tive, suggesting to be originated from the malignant phyl-
lodes tumor. Markers suggesting differentiation to smooth
muscle, α-smooth muscle actin, and Calponin1 were par-
tially positive. CD44 was positive. MIB-1 was highly posi-
tive (≥ 70 %), and p53 was strongly overexpressed.
Angiogenesis in the tumor was frequently observed as
demonstrated by high expression level of vascular endo-
thelial growth factor receptor-2 (VEGFR2) (Flk-1) in
tumor vessels.
Discussion
Once patients with malignant phyllodes tumor devel-
oped metastasis, their prognosis is extremely poor. After
the development of metastases, the mean overall survival
is 30 months [5]. For phyllodes tumors, complete surgi-
cal resection with wide margins is the fundamental treat-
ment to prevent metastasis [6,7]. Despite the complete
surgical resection, local failure rates range between 20
and 30 % for malignant tumors [8–10].
Approximately 22 % of cases of malignant phyllodes
tumor may give rise to hematogenous metastases. In a
review of 67 patients who had metastatic phyllodes tu-
mors, Kessinger and colleagues described the frequency
of metastasis in each site: lungs (66 %), bones (28 %),
heart (9 %), and liver (6 %).
In most cases, the metastases resemble to the sar-
comatous component of the primary tumor [11]. The
role of any adjuvant therapy, such as chemotherapy,
hormonal therapy, and even radiotherapy remains un-
clear [12].
Cardiac metastasis of malignant phyllodes tumor is
very rare. To our knowledge, there are only four
cases that underwent cardiac surgery for the metasta-
sis (Table 1) [13–16].
In four out of the five cases including our cases, tu-
mors were metastasized to the right ventricle and one to
the left atrium. In these cases, debulking surgery could
avoid sudden death, although most cases had unstable
condition after the surgery and showed poor prognosis.
Surgery to cardiac metastasis has a chance to avoid
Fig. 3 Histologic and immunohistochemical findings of metastatic tumor of the heart: formalin-fixed and paraffin-embedded slices were immunostained,
a α-smooth muscle actin and b Calponin1, c tumor suppressor, p53, and d VEGFR2 (Flk-1). Bars indicate 100 μm
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sudden death and improve the patients’ quality of life
and spend better the rest of their lives, regardless of how
short and low the quality of their lives are even after the
cardiac surgery. The patient strongly hoped to undergo
the surgery to have a possibility to prolong her life with
her children for a couple of months. After the surgery,
her symptom of heart failure was decreased and she and
her family could be satisfied to spend the rest of her life
at her home.
In the current study, markers that were frequently
observed in undifferentiated and high-grade sarcoma
were shown in immunohistochemical findings of the
specimen. The tumor was suspected to have been
originated from myoepithelial cells because of the
expression of smooth muscle lineage with Calponin1.
Expression of basic calponin has proved not only to
smooth muscle cells but also in cells with certain
smooth muscle-like phenotypes including myofibro-
blasts, myoepthelial cells, leiomyosarcomas, synovial
sarcomas, and a subset of osteosarcomas [17]. It also
showed highly malignant characteristics evidenced by
the presence of many cells suggesting high prolifera-
tion with highly positive MIB-1 and p53 expression.
MIB-1 and p53 expression has been reported as a
marker of aggressiveness in many tumors. In the
phyllodes tumor, the expression level of p53, tumor
angiogenesis, and MIB-1 have been described to re-
flect the degree of malignancy [18], although these
are not correlated with their prognosis.
Belkacémi and colleagues reported that in 159
patients with malignant and borderline phyllodes
tumor, radiotherapy significantly decreased local recur-
rence rate (p = 0.02) [20]. In a prospective study of 46
patients with borderline or malignant phyllodes tumor
who underwent breast-conserving surgery with adju-
vant radiotherapy, none of the 46 patients developed a
local recurrence with a median follow-up of 56 months
[19]. Although she did not receive irradiation therapy
because of her predicted short prognosis, radiotherapy
rather than chemotherapy in adjuvant setting may have
a good potential for patients with malignant phyllodes
tumor after surgical resection for local control and pre-
vention of metastasis.
Conclusions
We experienced a rare case of malignant phyllodes
tumor of the breast with high malignant characteristics
that was originated from myoepithelial cells and devel-
oped cardiac metastasis shortly after the removal of the
primary breast tumor. Our experience indicated that
mass reduction surgery of cardiac metastasis of malig-
nant phyllodes tumor might be an option for avoiding
sudden death and improving patients’ quality of life, re-
gardless of the extremely poor prognosis. Further large
studies are needed to clarify the effective treatment to
these tumors.
Abbreviations
HER2: human epidermal growth factor receptor type2; RV: right ventricle;
RVOT: RV outflow tract; SCC: squamous cell carcinoma.
Competing interests
The authors have stated that they have no conflicts of interest.
Authors’ contributions
All authors participated in drafting the article or revising it critically for
important intellectual content. KT, KS, and FA, carried out the immunoassays
and contributed to the interpretation of the data. All authors gave final
approval of the version to be published.
Author details
1Department of Breast Surgical Oncology, St. Luke’s International Hospital,
9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan. 2Department of Molecular
Medicine and Pathophysiology, Osaka Medical Center for Cancer and
Cardiovascular Disease, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511,
Japan. 3Department of Diagnostic Pathology, St. Luke’s International Hospital,
9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan. 4Division of Pathology,
Cancer institute Hospital of Japanese Foundation for Cancer Research, 3-8-31
Ariake, Koto-ku, Tokyo 135-8550, Japan. 5Department of Radiology, St. Luke’s
International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan.
6Department of Breast Surgical Oncology, Showa University School of
Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Received: 8 September 2015 Accepted: 20 November 2015
References
1. Rowell MD, Perry RR, Hsiu JG, Barranco SC. Phyllodes tumors. Am J Surg.
1993;165:376–79.
2. Calhoun K, Lawton TJ, Kim JM. Phyllodes tumors. In: Diseases of the breast.
In Harris J, Lippman ME, Osborne CK, M M (eds): Lippincott Williams and
Wilkins. Philadelphia, 2010;781.
3. Jones AM, Mitter R, Poulsom R, Gillett C, Hanby AM, Tomlinson IP, et al.
mRNA expression profiling of phyllodes tumours of the breast: identification
of genes important in the development of borderline and malignant
phyllodes tumours. J Pathol. 2008;216:408–17.
Table 1 Cases that underwent cardiac surgery for metastasis
Age Pre-operative
general status






Our case 38 Stable Mass reduction of RV, PA RV, PA 66 days 3 months
Garg et al. [13] 35 Cardiac shock Mass reduction of RV RV 8 days 3 years
Jackson et al. [14] 69 Unstable Mass reduction of RV, PA RV, PA 77 days 77 days
Myojin et al. [15] 47 Unstable Mass reduction of RV,
PATricuspid valve plasty
RV, PA 15 days 3 months
Nakatsu et al. [16] 69 Stable Mass reduction of LA LA 1 year (still alive) NA
LA left atrium, RV ventricle, PA pulmonary artery, NA not applicable
Yoshidaya et al. Surgical Case Reports  (2015) 1:121 Page 4 of 5
4. Rosenfeld JC, DeLaurentis DA, Lerner H. Cystosarcoma phyllodes. Diagnosis
and management. Cancer Clin Trials. 1981;4:187–93.
5. Kessinger A, Foley JF, Lemon HM, Miller DM. Metastatic cystosarcoma phyllodes:
a case report and review of the literature. J Surg Oncol. 1972;4:131–47.
6. Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Laé M, et al.
Management of phyllodes breast tumors. Breast J. 2011;17:129–37.
7. Khosravi-Shahi P. Management of non metastatic phyllodes tumors of the
breast: review of the literature. Surg Oncol. 2011;20:e143–48.
8. Ciatto S, Bonardi R, Cataliotti L, Cardona G. Phyllodes tumor of the breast: a
multicenter series of 59 cases. Coordinating Center and Writing Committee
of FONCAM (National Task Force for Breast Cancer), Italy. Eur J Surg Oncol.
1992;18:545–49.
9. Stebbing JF, Nash AG. Diagnosis and management of phyllodes tumour of
the breast: experience of 33 cases at a specialist centre. Ann R Coll Surg
Engl. 1995;77:181–4.
10. Zurrida S, Bartoli C, Galimberti V, Squicciarini P, Delledonne V, Veronesi P,
et al. Which therapy for unexpected phyllode tumour of the breast? Eur J
Cancer. 1992;28:654–57.
11. Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO. Phyllodes
tumours of the breast: a clinicopathological review of thirty-two cases.
Histopathology. 1995;27:205–18.
12. Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes
tumors of the breast: natural history, diagnosis, and treatment. J Natl
Compr Canc Netw. 2007;5:324–30.
13. Garg N, Moorthy N, Agrawal SK, Pandey S, Kumari N. Delayed cardiac
metastasis from phyllodes breast tumor presenting as cardiogenic shock.
Tex Heart Inst J. 2011;38:441–44.
14. Jackson CE, Gardner RS, Connelly DT. A novel approach for a novel
combination: a trans-septal biopsy of left atrial mass in recurrent phyllodes
tumour. Eur J Echocardiogr. 2009;10:171–72.
15. Myojin K, Murakami T, Ishii K, Kunihara T. An emergent operation for
metastatic cardiac tumor of malignant cystosarcoma phyllodes.
Jpn J Thorac Cardiovasc Surg. 1998;46:202–6.
16. Nakatsu T, Koshiji T, Sakakibara Y, Hagio K, Ishigami M, Arima Y, et al.
Pulmonary artery obstruction due to a metastatic malignant phyllodes
tumor of the breast. Gen Thorac Cardiovasc Surg. 2010;58:423–26.
17. Takahashi K, Yamamura H. Studies and perspectives of calponin in smooth
muscle regulation and cancer gene therapy. Adv Biophys. 2003;37:91–111.
18. Tse GMK, Lui PCW, Scolyer RA, Putti TC, Kung FY, Law BK, et al. Tumour
angiogenesis and p53 protein expression in mammary phyllodes tumors.
Mod Pathol. 2003;16:1007–13.
19. Barth Jr RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional
study of adjuvant radiotherapy after resection of malignant phyllodes
tumors. Ann Surg Oncol. 2009;16:2288–94.
20. Belkacémi Y1, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y,
et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys. 2008;70:
492–500.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Yoshidaya et al. Surgical Case Reports  (2015) 1:121 Page 5 of 5
